FI946104A - Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi - Google Patents

Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi Download PDF

Info

Publication number
FI946104A
FI946104A FI946104A FI946104A FI946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A
Authority
FI
Finland
Prior art keywords
preparation
particularly concentrated
concentrated immunoglobulin
immunoglobulin
highly concentrated
Prior art date
Application number
FI946104A
Other languages
English (en)
Swedish (sv)
Other versions
FI111224B (fi
FI946104A0 (fi
Inventor
Johann Eibl
Yendra Linnau
Wolfgang Teschner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI946104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI946104A0 publication Critical patent/FI946104A0/fi
Publication of FI946104A publication Critical patent/FI946104A/fi
Application granted granted Critical
Publication of FI111224B publication Critical patent/FI111224B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI946104A 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi FI111224B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
DE4344824 1993-12-28

Publications (3)

Publication Number Publication Date
FI946104A0 FI946104A0 (fi) 1994-12-27
FI946104A true FI946104A (fi) 1995-06-29
FI111224B FI111224B (fi) 2003-06-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946104A FI111224B (fi) 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi

Country Status (15)

Country Link
US (1) US5608038A (fi)
EP (1) EP0661060B1 (fi)
JP (1) JP3040678B2 (fi)
AT (2) AT407707B (fi)
CA (1) CA2138853A1 (fi)
CZ (1) CZ284186B6 (fi)
DE (2) DE4344824C1 (fi)
DK (1) DK0661060T3 (fi)
ES (1) ES2158877T3 (fi)
FI (1) FI111224B (fi)
HR (1) HRP941018B1 (fi)
HU (1) HU220766B1 (fi)
NO (1) NO315260B1 (fi)
RU (1) RU2104713C1 (fi)
YU (1) YU77994A (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
CN100360184C (zh) * 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AU2005267020B2 (en) * 2004-07-23 2011-08-11 Genentech, Inc. Crystallization of antibodies or fragments thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
RU2011140498A (ru) * 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CA2923844C (en) 2013-09-11 2022-07-26 Arsia Therapeutics, Inc. Liquid protein formulations containing organophosphates
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
EP3334747B1 (en) 2015-08-13 2023-09-27 Amgen Inc. Charged depth filtration of antigen-binding proteins
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
EP0168506B2 (en) * 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
HUT70449A (en) 1995-10-30
EP0661060B1 (de) 2001-05-23
NO945045D0 (no) 1994-12-27
ES2158877T3 (es) 2001-09-16
CZ284186B6 (cs) 1998-09-16
HRP941018A2 (en) 1997-04-30
EP0661060A3 (de) 1997-01-15
HU9403795D0 (en) 1995-02-28
RU2104713C1 (ru) 1998-02-20
JP3040678B2 (ja) 2000-05-15
CZ328494A3 (en) 1995-07-12
DK0661060T3 (da) 2001-07-30
CA2138853A1 (en) 1995-06-29
HU220766B1 (hu) 2002-05-28
ATA237894A (de) 2000-10-15
YU77994A (sh) 1997-03-07
DE59409761D1 (de) 2001-06-28
AT407707B (de) 2001-05-25
FI111224B (fi) 2003-06-30
EP0661060A2 (de) 1995-07-05
FI946104A0 (fi) 1994-12-27
US5608038A (en) 1997-03-04
HRP941018B1 (en) 1999-12-31
JPH07206709A (ja) 1995-08-08
NO315260B1 (no) 2003-08-11
DE4344824C1 (de) 1995-08-31
ATE201328T1 (de) 2001-06-15
NO945045L (no) 1995-06-29

Similar Documents

Publication Publication Date Title
FI946104A (fi) Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi
AU5612694A (en) Injectable composition
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
ZA924999B (en) New compositions containing taxane derivatives
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
ATE141498T1 (de) Sonnenschutzmittel
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
FR2635780B1 (fr) Diorganopolysiloxane a fonction benzotriazole
ATE159713T1 (de) N-acylglutamin-derivate
BR9401198A (pt) Massas de polietileno
PH27567A (en) Topical compositions
YU46914B (sh) Metoksimetilna jedinjenja
CA2070421A1 (fr) Agent edulcorant derivant de l'acide l-aspartique ou l-glutamique; son procede de preparation
KR910000901A (ko) 폴리에틸렌 조성물
ITMI920084A1 (it) Alchil derivati del trazodone
PT97663A (pt) Processo de preparacao de 3'-desamino-4'-desoxi-4'-amino-8-fluoro-antraciclinas, de composicoes farmaceuticas que as contem e de seus intermediarios
ES2021334B3 (es) Composiciones de caucho que contienen derivados aminicos del 1,3,4-triadiazol.
KR890003380A (ko) 피부에 축적하는 외용의 항 바이러스성 약학적 조성물 및 그 제조방법
AU1508592A (en) Sweetening agents derived from l-glutamic acid and their method of preparation
DK0533089T3 (da) Flydende peroxidiske sammensætninger
DE3586286D1 (de) Verwendung von pyrrothinderivaten.
KR870008535A (ko) "밤"가루(율분)

Legal Events

Date Code Title Description
MA Patent expired